Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CANbridge Pharmaceuticals Inc. ( (HK:1228) ) has shared an update.
CANbridge Pharmaceuticals Inc. announced that all resolutions, except one which was withdrawn, were approved at their Annual General Meeting held on June 27, 2025. The resolutions included re-electing directors, authorizing board remuneration, reappointing the auditor, and granting mandates for share issuance and repurchase. This outcome reflects strong shareholder support and positions the company for continued strategic initiatives in its industry.
More about CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases and targeted cancers. The company operates primarily in the pharmaceutical industry, aiming to address unmet medical needs in these specialized markets.
Average Trading Volume: 5,318,857
Technical Sentiment Signal: Buy
Current Market Cap: HK$142.3M
See more data about 1228 stock on TipRanks’ Stock Analysis page.